GlassScriptPhysician profile
Anil Davanand Mankee
NPI 1538472725
$10,419.28
in general payments reported to CMS, 2019-2025
32 companies · $4,445 in 2025
The $4,445 reported for 2025 was more than what 84% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,987 · 2020: $366 · 2021: $23.01 · 2023: $234 · 2024: $3,366 · 2025: $4,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,945 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,944.67 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,551.31 | 2019-2025 | |
| Amgen INC. | $1,661.79 | 2019-2025 | Enbrel, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $972.72 | 2019-2025 | |
| Ucb, INC. | $901.64 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $869.86 | 2019-2025 | Tremfya |
| Pfizer INC. | $520.85 | 2019-2025 | |
| Radius Health, INC. | $361.99 | 2024-2025 | Tymlos |
| Mallinckrodt Hospital Products INC. | $312.92 | 2020-2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $290.78 | 2019-2025 | Orencia |
| Mallinckrodt Enterprises LLC | $284.28 | 2019 | |
| Ani Pharmaceuticals, INC. | $248.05 | 2024-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $223.38 | 2019-2024 | Taltz |
| Glaxosmithkline, LLC. | $219.47 | 2024-2025 | Benlysta |
| Celgene Corporation | $128.17 | 2019 | |
| Alexion Pharmaceuticals, INC. | $118.16 | 2019-2025 | Strensiq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $102.45 | 2024-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.75 | 2023-2025 | Ofev |
| Sanofi-Aventis U.S. LLC | $85.52 | 2019 | |
| Genentech USA, INC. | $78.76 | 2019-2023 | Actemra |
| Horizon Therapeutics Plc | $64.06 | 2019 | |
| Pacira Therapeutics, INC. | $49.93 | 2019 | |
| Sandoz INC. | $45.04 | 2024 | Hyrimoz |
| Organon LLC | $41.10 | 2025 | Hadlima, Renflexis |
| Medexus Pharma, INC. | $31.87 | 2019 | |
| Genzyme Corporation | $29.89 | 2025 | |
| Aurinia Pharma U.S., INC. | $27.88 | 2024 | Lupkynis |
| Abbott Laboratories | $21.98 | 2024 | Proclaim |
| Fresenius Kabi USA, LLC | $19.92 | 2024 | Tyenne |
| Actelion Pharmaceuticals US, INC. | $16.43 | 2025 | Opsumit |
| Ferring Pharmaceuticals INC. | $16.22 | 2019 | |
| Smith+Nephew, INC. | $14.13 | 2019 | |
| Sobi, INC | $11.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Mankee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.